The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
Edmund Poon(National Cancer Centre Singapore), Robert W. Wilkinson(Immunocore (United Kingdom))
Cited by 75
Related Papers
MHC class I chain-related protein A and B (MICA and MICB) are predominantly expressed intracellularly in tumour and normal tissue
|British Journal of Cancer|2017|110